30,400 Shares in SI-BONE, Inc. (NASDAQ:SIBN) Purchased by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC purchased a new position in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 30,400 shares of the company's stock, valued at approximately $426,000. Schonfeld Strategic Advisors LLC owned about 0.07% of SI-BONE as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently added to or reduced their stakes in SIBN. Invesco Ltd. boosted its stake in SI-BONE by 8.9% in the fourth quarter. Invesco Ltd. now owns 17,203 shares of the company's stock valued at $241,000 after acquiring an additional 1,413 shares during the last quarter. Rhumbline Advisers lifted its stake in SI-BONE by 3.0% in the fourth quarter. Rhumbline Advisers now owns 57,621 shares of the company's stock valued at $808,000 after purchasing an additional 1,683 shares during the last quarter. Barclays PLC grew its holdings in SI-BONE by 2.7% during the fourth quarter. Barclays PLC now owns 99,212 shares of the company's stock valued at $1,391,000 after purchasing an additional 2,589 shares during the period. Alliancebernstein L.P. increased its position in SI-BONE by 6.2% in the fourth quarter. Alliancebernstein L.P. now owns 55,750 shares of the company's stock worth $782,000 after buying an additional 3,250 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of SI-BONE by 11.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 31,742 shares of the company's stock valued at $446,000 after buying an additional 3,318 shares during the period. Institutional investors own 98.11% of the company's stock.

SI-BONE Price Performance

SIBN traded up $0.16 on Wednesday, reaching $18.75. The company had a trading volume of 624,249 shares, compared to its average volume of 371,507. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $19.35. The company has a market cap of $799.03 million, a price-to-earnings ratio of -20.38 and a beta of 0.82. The business has a 50 day simple moving average of $14.61 and a 200 day simple moving average of $14.90.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The business had revenue of $47.29 million for the quarter, compared to analysts' expectations of $45.13 million. As a group, sell-side analysts anticipate that SI-BONE, Inc. will post -0.78 EPS for the current year.

Insider Buying and Selling at SI-BONE

In related news, CEO Laura Francis sold 38,504 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were sold at an average price of $17.18, for a total transaction of $661,498.72. Following the transaction, the chief executive officer now owns 302,958 shares in the company, valued at $5,204,818.44. The trade was a 11.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Anshul Maheshwari sold 4,937 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $17.00, for a total transaction of $83,929.00. Following the completion of the sale, the chief financial officer now owns 265,356 shares of the company's stock, valued at $4,511,052. This trade represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,216 shares of company stock valued at $841,138 in the last 90 days. Insiders own 4.00% of the company's stock.

Analyst Upgrades and Downgrades

SIBN has been the subject of several recent research reports. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price objective on shares of SI-BONE in a research note on Tuesday, May 6th. Truist Financial boosted their price target on shares of SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price objective on shares of SI-BONE in a report on Tuesday, May 6th.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.